Bio-Techne (TECH), a life science company, on Friday announced the launch of a new line of AI-engineered designer proteins aimed at advancing cell therapy and regenerative medicine.
The expanded portfolio, developed under the company's R&D Systems brand, includes advanced proteins like IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable, and Wnt/RSPO agonists.
These proteins are engineered using cutting-edge AI technology and evolutionary protein design to address key needs in cellular therapy, such as improved cell culture performance and optimized cell expansion.
The new products are designed for a variety of applications, including CAR T-cell and tumor-infiltrating lymphocyte (TIL) expansion, stem cell culture, and regenerative medicine.
Will Geist, President of the Protein Sciences Segment at Bio-Techne, stated, "Our growing portfolio combines cutting-edge AI technology and innovative protein engineering, empowering customers with high-performance solutions to enhance cell therapy production and regenerative medicine efforts."
The new products include:
Optimized for cellular therapy applications like CAR T-cell expansion.
Designed for superior regenerative medicine cell differentiation.
A versatile growth factor for stem cell culture, available in both research-use-only (RUO) and GMP formats.
Key reagents for stem cell research and organoid development.
Bio-Techne continues to develop next-generation tools for cell therapy and regenerative medicine research, aiming to provide breakthrough solutions for researchers and clinicians.
Currently TECH is trading at $74.74 down by 0.60%
For comments and feedback: editorial@rttnews.com